clinical trial · NCT07158398
Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
Deciphera Pharmaceuticals, LLC·phase1·completed·n = 20
Healthy ParticipantsVimseltinibRosuvastatin
brief summary
The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male participants. This study will also evaluate the safety and tolerability when vimseltinib is co-administered with rosuvastatin in healthy male participants. This study will last approximately 26 days.
started
Oct 31, 2025
primary completion
Dec 8, 2025
completion
Dec 8, 2025
last updated
Jan 15, 2026
official title
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Vimseltinib on BCRP and OATP1B1 Inhibition in Healthy Male Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol